scholarly journals High Throughput Sequencing Detect Gingivitis And Periodontal Oral Bacteria In Alzheimer’s Disease Autopsy Brains

2019 ◽  
Vol 1 (1) ◽  
Author(s):  
Huma Siddiqui ◽  
Emenike RK Eribe ◽  
Sim K Singhrao ◽  
Ingar Olsen
2020 ◽  
Vol 74 (4) ◽  
pp. 1285-1294 ◽  
Author(s):  
Insa Feinkohl ◽  
Carola G. Schipke ◽  
Jochen Kruppa ◽  
Felix Menne ◽  
Georg Winterer ◽  
...  

2017 ◽  
Vol 13 (7S_Part_21) ◽  
pp. P1034-P1034
Author(s):  
Pablo San Segundo-Acosta ◽  
Ana Montero-Calle ◽  
Maria Garranzo-Asensio ◽  
Carmen Oeo-Santos ◽  
Juan Carlos López-Rodríguez ◽  
...  

2020 ◽  
Vol 79 (6) ◽  
pp. 568-584 ◽  
Author(s):  
Peter T Nelson ◽  
David W Fardo ◽  
Yuriko Katsumata

Abstract We recently reported evidence of Alzheimer’s disease (AD)-linked genetic variation within the mucin 6 (MUC6) gene on chromosome 11p, nearby the adaptor-related protein complex 2 subunit alpha 2 (AP2A2) gene. This locus has interesting features related to human genomics and clinical research. MUC6 gene variants have been reported to potentially influence viral—including herpesvirus—immunity and the gut microbiome. Within the MUC6 gene is a unique variable number of tandem repeat (VNTR) region. We discovered an association between MUC6 VNTR repeat expansion and AD pathologic severity, particularly tau proteinopathy. Here, we review the relevant literature. The AD-linked VNTR polymorphism may also influence AP2A2 gene expression. AP2A2 encodes a polypeptide component of the adaptor protein complex, AP-2, which is involved in clathrin-coated vesicle function and was previously implicated in AD pathogenesis. To provide background information, we describe some key knowledge gaps in AD genetics research. The “missing/hidden heritability problem” of AD is highlighted. Extensive portions of the human genome, including the MUC6 VNTR, have not been thoroughly evaluated due to limitations of existing high-throughput sequencing technology. We present and discuss additional data, along with cautionary considerations, relevant to the hypothesis that MUC6 repeat expansion influences AD pathogenesis.


2019 ◽  
Vol 15 ◽  
pp. P285-P286
Author(s):  
Jorge Alberto Bahena ◽  
Fabiana H.G. Farias ◽  
Kathie A. Mihindukulasuriya ◽  
John P. Budde ◽  
Carlos Cruchaga ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Kyu-Young Sim ◽  
Sang-Heon Park ◽  
Kyu Yeong Choi ◽  
Jung Eun Park ◽  
Jung Sup Lee ◽  
...  

2021 ◽  
Vol 17 ◽  
Author(s):  
Minmin Zhang ◽  
Siduo Zhou ◽  
Wei Liu ◽  
Huijiao Yan ◽  
Xiao Wang ◽  
...  

Background: Salviae Miltiorrhizae Radix et Rhizoma (Red Sage root) is widely used in traditional Chinese medicine (TCM) for the treatment of Alzheimer’s disease (AD) with demonstrated curative effects, based on the concept of "one drug with multiple therapeutic targets," which appears to be a good strategy for AD treatment. Objective: This study aimed to develop of high-throughput screening (HTS) method for multi-therapeutic target components found in complex TCMs, which are active against AD, using Red Sage root as the case study. Method: Acetylcholinesterase (AChE) inhibitors (AChEIs) from Red Sage root extracts were pre-screened by ultrafiltration-HPLC (UF-HPLC) analysis, in which AChE was added to the extract and then ultrafiltered to remove non-binding compounds. Potential AChEIs were identified by HPLC analysis of compounds bound to AChE. A microplate-based HTS was then used to quantify the AChE inhibitory activity and antioxidant activity of the pre-screened compounds. Results: Pre-screening found ten potential inhibitors, which were identified by ESI-TOF/MS; six of these were purified by semi-preparative HPLC: Oleoyl neocryptotanshinone (1), Dihydrotanshinone Ⅰ (2), Cryptotanshinone (3), Tanshinone Ⅰ (4), Tanshinone ⅡA (5) and Miltirone (6). All six compounds had good AChE inhibitory activity and weak DPPH scavenging capacity. Conclusion: This study provides a platform and technology support for the rapid discovery of multi-target components, potentially active against AD, from complex TCMs and with strong potential for adaptation to the discovery of treatments for other diseases.


Sign in / Sign up

Export Citation Format

Share Document